|  |
Signals' Mission
Signals is an online magazine of analysis for biotechnology executives. Our mission is to provide comprehensive, timely analysis of major trends and new developments critical to the pursuit of novel new medical therapies and diagnostic products utilizing advanced technology. Our main areas of emphasis are alliances, financial trends, technology developments, and profiles of interesting people and companies. |
Signals' Staff & Contributors
Signals is proud to feature the work of experienced science and business journalists.
STAFF
Editor
Jennifer Van Brunt, Ph.D., joined Signals as its new editor in April 1999, bringing with her 15 years of experience covering the biotechnology industry as a journalist and reporter. Before joining Signals, Jennifer was the editor of BioWorld Financial Watch, a weekly fax publication that covers trends in the biotech industry. She also held a position as senior editor at BioWorld Today. Prior to joining the BioWorld group, Jennifer was the managing editor at Bio/Technology (now known as Nature Biotechnology). Concurrently, she was an associate professor in the adjunct faculty of the department of biochemistry and molecular biology at the University of Miami School of Medicine. She received her Ph.D. degree in genetics from the University of California at Davis and went on to hold positions as a postdoctoral fellow and a research associate at the National Jewish Center for Immunology and Respiratory Medicine in Denver.
E-mail: jvanbrunt@deloitte.com
Current Contributors
Ken Garber is a Michigan-based science writer. A former staff writer for the Ann Arbor Observer, he now writes for Science, Technology Review, Nature Biotechnology, Nature Medicine and the Journal of the National Cancer Institute.
E-mail: KENGARBER@prodigy.net
Bruce Goldman is a San Francisco-based freelance writer who has been covering health and biotechnology since 1983, when, as a graduate student studying cell biology at Harvard University, he wrote several articles for the Harvard Medical School Health Letter. His work has appeared in Health, Hippocrates, Genetic Engineering News, Parenting, Stanford Medicine, the Miami Herald, San Francisco Chronicle and Examiner, San Jose Mercury News, and other publications. Bruce has held top editorial slots at MoreLife, a preventive-health magazine; the Stanford University-based Portable Stanford Book Series; and Bechtel Briefs, an award-winning corporate magazine of Bechtel Group, Inc. He is also former associate editor of Stanford Magazine and co-author of two books on technological, demographic, environmental, economic, and social trends -- Fast Forward: Where Technology, Demographics, and History Will Take America and the World in the Next Thirty Years (Harper Business, 1994) and 2020 Visions: Long View of a Changing World (Portable Stanford Book Series, 1991).
E-mail: brucegoldman@earthlink.net
Tom Hollon, Ph.D., is a science writer and editor based in Rockville, MD. He was the founding editor of Modern Drug Discovery and conducted research at the National Institutes of Health, the Pasteur Institute and the University of Washington. His articles have appeared in The Scientist, Nature Medicine, Nature Biotechnology and The Lancet. He has a Ph.D. in microbiology from the University of Washington and the Hutchinson Cancer Center.
Email: thollon@starpower.net
Lisa Piercey has worked in or written about the biotechnology industry since 1988. She was the Business Editor and founder of BioWorld Financial Watch and the Washington Editor of BioWorld Today. Her articles have appeared in BioWorld Today, BioWorld Financial Watch, BioPeople, Pharmaceutical Outcomes News, Outcomes Measurement & Management and the BBI Newsletter. Prior to joining BioWorld, Lisa was employed at XOMA Corp. where she worked on the FDA advisory committee presentations for two experimental agents. She has a masters degree in international affairs from Columbia University. While in graduate school, Lisa worked at Newsweek International.
E-mail: lnatanson@deloitte.com
|
Signals is published by Recap, a San Francisco Bay-based consulting firm specializing in biotechnology alliances and capitalization.
Recap's mission is to make available adequate resources for biotechnology enterprises by providing comprehensive and timely advice and analysis related to the environment for corporate and product development and alliance formation. Recap's clients include biotechnology and pharmaceutical companies, plus several universities, investment banking and venture firms active in the biotechnology area. More than 1,500 organizations have subscribed to Recap's data services.
In 1988 Mark Edwards founded Recombinant Capital, Inc. a San Francisco Bay Area-based consulting firm specializing in biotechnology alliances, clinical development, product sales, company information and capitalization. Prior to founding the company, Mr. Edwards was manager of business development at Chiron. Mr. Edwards earned a bachelor's degree in economics and an MBA, both from Stanford University. In 2008, Recombinant Capital, Inc. was purchased by Deloitte LLP and the business is now known as Deloitte Recap LLC ("Recap").
For more information, follow this link. Or call Recap at 925-952-3870.
Deloitte Recap Team |
|